Cargando…

Leukocyte- and platelet-rich fibrin in cranial surgery: study protocol for a prospective, parallel-group, single-blinded randomized controlled non-inferiority trial {1}

BACKGROUND: CSF leakage is a major complication after cranial surgery, thus, adequate dural closure must be performed. Commercially available fibrin sealants are currently considered the gold standard for dural closure, but problems have been reported regarding safety, efficacy, and costs. This tria...

Descripción completa

Detalles Bibliográficos
Autores principales: Coucke, Birgit, Van Hoylandt, Anaïs, van Loon, Johannes, Van Calenbergh, Frank, Van Gerven, Laura, Theys, Tom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034240/
https://www.ncbi.nlm.nih.gov/pubmed/36959672
http://dx.doi.org/10.1186/s13063-023-07252-w
_version_ 1784911169774944256
author Coucke, Birgit
Van Hoylandt, Anaïs
van Loon, Johannes
Van Calenbergh, Frank
Van Gerven, Laura
Theys, Tom
author_facet Coucke, Birgit
Van Hoylandt, Anaïs
van Loon, Johannes
Van Calenbergh, Frank
Van Gerven, Laura
Theys, Tom
author_sort Coucke, Birgit
collection PubMed
description BACKGROUND: CSF leakage is a major complication after cranial surgery, thus, adequate dural closure must be performed. Commercially available fibrin sealants are currently considered the gold standard for dural closure, but problems have been reported regarding safety, efficacy, and costs. This trial aims to investigate autologous leukocyte- and platelet-rich fibrin (L-PRF) as an alternative to commercially available fibrin sealants. METHODS/DESIGN: This single-blinded, prospective randomized controlled interventional trial aims to demonstrate the non-inferiority of L-PRF compared to commercially available fibrin sealants for dural closure. This trial will include patients undergoing cranial neurosurgery (supratentorial and infratentorial) with intentional opening of the dura. Patients are randomized in a 1:1 fashion comparing L-PRF to commercially available fibrin sealants. The primary endpoint is postoperative CSF leakage within 12 weeks after surgery. Secondary endpoints are complications such as bleeding or wound infections. Additionally, a cost-effectiveness analysis is performed. DISCUSSION: With this trial, we will evaluate the safety and efficiency of L-PRF compared to commercially available fibrin sealants. TRIAL REGISTRATION: ClinicalTrials.gov NCT03812120. Registered on 22 January 2019. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-023-07252-w.
format Online
Article
Text
id pubmed-10034240
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-100342402023-03-23 Leukocyte- and platelet-rich fibrin in cranial surgery: study protocol for a prospective, parallel-group, single-blinded randomized controlled non-inferiority trial {1} Coucke, Birgit Van Hoylandt, Anaïs van Loon, Johannes Van Calenbergh, Frank Van Gerven, Laura Theys, Tom Trials Study Protocol BACKGROUND: CSF leakage is a major complication after cranial surgery, thus, adequate dural closure must be performed. Commercially available fibrin sealants are currently considered the gold standard for dural closure, but problems have been reported regarding safety, efficacy, and costs. This trial aims to investigate autologous leukocyte- and platelet-rich fibrin (L-PRF) as an alternative to commercially available fibrin sealants. METHODS/DESIGN: This single-blinded, prospective randomized controlled interventional trial aims to demonstrate the non-inferiority of L-PRF compared to commercially available fibrin sealants for dural closure. This trial will include patients undergoing cranial neurosurgery (supratentorial and infratentorial) with intentional opening of the dura. Patients are randomized in a 1:1 fashion comparing L-PRF to commercially available fibrin sealants. The primary endpoint is postoperative CSF leakage within 12 weeks after surgery. Secondary endpoints are complications such as bleeding or wound infections. Additionally, a cost-effectiveness analysis is performed. DISCUSSION: With this trial, we will evaluate the safety and efficiency of L-PRF compared to commercially available fibrin sealants. TRIAL REGISTRATION: ClinicalTrials.gov NCT03812120. Registered on 22 January 2019. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-023-07252-w. BioMed Central 2023-03-23 /pmc/articles/PMC10034240/ /pubmed/36959672 http://dx.doi.org/10.1186/s13063-023-07252-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Study Protocol
Coucke, Birgit
Van Hoylandt, Anaïs
van Loon, Johannes
Van Calenbergh, Frank
Van Gerven, Laura
Theys, Tom
Leukocyte- and platelet-rich fibrin in cranial surgery: study protocol for a prospective, parallel-group, single-blinded randomized controlled non-inferiority trial {1}
title Leukocyte- and platelet-rich fibrin in cranial surgery: study protocol for a prospective, parallel-group, single-blinded randomized controlled non-inferiority trial {1}
title_full Leukocyte- and platelet-rich fibrin in cranial surgery: study protocol for a prospective, parallel-group, single-blinded randomized controlled non-inferiority trial {1}
title_fullStr Leukocyte- and platelet-rich fibrin in cranial surgery: study protocol for a prospective, parallel-group, single-blinded randomized controlled non-inferiority trial {1}
title_full_unstemmed Leukocyte- and platelet-rich fibrin in cranial surgery: study protocol for a prospective, parallel-group, single-blinded randomized controlled non-inferiority trial {1}
title_short Leukocyte- and platelet-rich fibrin in cranial surgery: study protocol for a prospective, parallel-group, single-blinded randomized controlled non-inferiority trial {1}
title_sort leukocyte- and platelet-rich fibrin in cranial surgery: study protocol for a prospective, parallel-group, single-blinded randomized controlled non-inferiority trial {1}
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034240/
https://www.ncbi.nlm.nih.gov/pubmed/36959672
http://dx.doi.org/10.1186/s13063-023-07252-w
work_keys_str_mv AT couckebirgit leukocyteandplateletrichfibrinincranialsurgerystudyprotocolforaprospectiveparallelgroupsingleblindedrandomizedcontrollednoninferioritytrial1
AT vanhoylandtanais leukocyteandplateletrichfibrinincranialsurgerystudyprotocolforaprospectiveparallelgroupsingleblindedrandomizedcontrollednoninferioritytrial1
AT vanloonjohannes leukocyteandplateletrichfibrinincranialsurgerystudyprotocolforaprospectiveparallelgroupsingleblindedrandomizedcontrollednoninferioritytrial1
AT vancalenberghfrank leukocyteandplateletrichfibrinincranialsurgerystudyprotocolforaprospectiveparallelgroupsingleblindedrandomizedcontrollednoninferioritytrial1
AT vangervenlaura leukocyteandplateletrichfibrinincranialsurgerystudyprotocolforaprospectiveparallelgroupsingleblindedrandomizedcontrollednoninferioritytrial1
AT theystom leukocyteandplateletrichfibrinincranialsurgerystudyprotocolforaprospectiveparallelgroupsingleblindedrandomizedcontrollednoninferioritytrial1